Cartography Biosciences secured $67 million in a Series B financing round led by Pfizer Ventures to advance its lead T-cell engaging bispecific antibody program targeting colorectal cancer. The biotech employs data-driven platform technologies analyzing healthy and cancerous cells to identify highly specific tumor antigens, positioning it to innovate immunotherapy options for colorectal malignancies with significant unmet needs.